Press release
Cutaneous Squamous cell Carcinom Treatment Market Size Report 2034: Emerging Therapies and Future Growth Opportunities
Cutaneous Squamous cell Carcinoma Treatment Market
Discover Key Insights into the Cutaneous Squamous Cell Carcinoma Market with DelveInsight's In-Depth Report @ Cutaneous Squamous Cell Carcinoma Market Size- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Cutaneous Squamous Cell Carcinoma Market Report
• In March 2025, Merck Sharp & Dohme LLC initiated a study to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) pembrolizumab combined with berahyaluronidase alfa in Japanese participants with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced unresectable cSCC. The primary hypothesis of the study is that pembrolizumab in combination with berahyaluronidase alfa will achieve an objective response rate (ORR) greater than 10%, as assessed by Blinded Independent Central Review (BICR) using the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
• Men were more likely to have Cutaneous Squamous Cell Carcinoma arise on the head and neck, whereas women were more likely to have Cutaneous Squamous Cell Carcinoma develop on the lower extremity.
• The highest Incident cases of cSCC occurred in the age groups ≥60 years.
• Cutaneous Squamous Cell Carcinoma Incidence is higher in men than women.
• The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Melanoma Institute Australia, Replimune Inc., Stanford University, Regeneron Pharmaceuticals, Shanghai Henlius Biotech, Merck Sharp & Dohme LLC, Philogen S.p.A., Queensland Health, Sanofi, and others.
• Promising Cutaneous Squamous Cell Carcinoma Therapies such as INCB099280, Nivolumab, Atezolizumab, cemiplimab, HLX07, MK-3475A, L19IL2 +L19TNF, Pembrolizumab, THOR-707, and others
Stay ahead in the Cutaneous Squamous Cell Carcinoma Therapeutics Market with DelveInsight's Strategic Report @ Cutaneous Squamous Cell Carcinoma Market Outlook- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cutaneous Squamous Cell Carcinoma Epidemiology Segmentation in the 7MM
• Total Prevalence of Cutaneous Squamous Cell Carcinoma
• Prevalent Cases of Cutaneous Squamous Cell Carcinoma by severity
• Gender-specific Prevalence of Cutaneous Squamous Cell Carcinoma
• Diagnosed Cases of Episodic and Chronic Cutaneous Squamous Cell Carcinoma
Download the report to understand which factors are driving Cutaneous Squamous Cell Carcinoma Epidemiology trends @ Cutaneous Squamous Cell Carcinoma Epidemiological Insights- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cutaneous Squamous Cell Carcinoma Marketed Drugs
• KEYTRUDA: Merck
Merck's KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. In June 2020, the US FDA approved KEYTRUDA as monotherapy for the treatment of patients with recurrent or metastatic CSCC that is not curable by surgery or radiation. This approval was based on data from the Phase II KEYNOTE-629 trial.
• LIBTAYO: Regeneron Pharmaceuticals/ Medison Pharma
LIBTAYO (cemiplimab) is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. It is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. The US FDA granted the approval of LIBTAYO to Regeneron Pharmaceuticals in September 2018.
Cutaneous Squamous Cell Carcinoma Emerging Drugs
• Cosibelimab (CK-301): Checkpoint Therapeutics
Cosibelimab (CK-301) is an investigational fully-human monoclonal antibody that targets the PD-1/PD-L1 pathway to treat various cancers. It is being evaluated in a global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).
• INCB99280: Incyte Corporation
INCB099280 is a novel targeted therapy that is being developed to treat advanced cSCC, which is an aggressive form of skin cancer. Incyte Corporation is conducting a Phase II clinical trial (NCT05888844) to assess the safety, tolerability, and initial efficacy of INCB099280 in advanced cutaneous squamous cell carcinoma (cSCC). The study comprises two parts: Part 1 involves random assignment of participants with metastatic or locally advanced cSCC to three different dose levels of INCB099280 to determine the optimal dose. Part 2 will expand on the chosen dose from Part 1, evaluating clinical response rates, response duration, and safety in a larger group of patients with metastatic or locally advanced cSCC.
To learn more about Cutaneous Squamous Cell Carcinoma treatment guidelines, visit @ Cutaneous Squamous Cell Carcinoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cutaneous Squamous Cell Carcinoma Therapies and Key Companies
• INCB099280: Incyte Corporation
• Nivolumab: Melanoma Institute Australia
• Atezolizumab: Stanford University
• cemiplimab: Regeneron Pharmaceuticals
• HLX07: Shanghai Henlius Biotech
• MK-3475A: Merck Sharp & Dohme LLC
• L19IL2 +L19TNF: Philogen S.p.A.
• Pembrolizumab: Queensland Health
• THOR-707: Sanofi
Cutaneous Squamous Cell Carcinoma Market Strengths
• Ongoing research and advancements in the understanding of CSCC may lead to the development of new treatment options and targeted therapies.
• Improvements in diagnostic tools, such as imaging techniques and biopsy methods, contribute to early and accurate diagnosis, allowing for timely intervention.
Cutaneous Squamous Cell Carcinoma Market Opportunities
• Early detection of precursor lesions, appropriate diagnosis, and staging of CSCCs is key to providing patients with appropriate prognostic information.
• Continued advancements in immunotherapy may offer new and more effective treatment options for CSCC, harnessing the body's immune system to fight cancer.
Learn more about the FDA-approved drugs for Cutaneous Squamous Cell Carcinoma @ Drugs for Cutaneous Squamous Cell Carcinoma Treatment- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Cutaneous Squamous Cell Carcinoma Market Report
• Coverage: 7MM
• Study Period- 2020-2034
• Cutaneous Squamous Cell Carcinoma Companies: Incyte Corporation, Melanoma Institute Australia, Replimune Inc., Stanford University, Regeneron Pharmaceuticals, Shanghai Henlius Biotech, Merck Sharp & Dohme LLC, Philogen S.p.A., Queensland Health, Sanofi, and others
• Cutaneous Squamous Cell Carcinoma Therapies: INCB099280, Nivolumab, Atezolizumab, cemiplimab, HLX07, MK-3475A, L19IL2 +L19TNF, Pembrolizumab, THOR-707, and others
• Cutaneous Squamous Cell Carcinoma Therapeutic Assessment: Cutaneous Squamous Cell Carcinoma current marketed and Cutaneous Squamous Cell Carcinoma emerging therapies
• Cutaneous Squamous Cell Carcinoma Market Dynamics: Cutaneous Squamous Cell Carcinoma market drivers and Cutaneous Squamous Cell Carcinoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cutaneous Squamous Cell Carcinoma Unmet Needs, KOL's views, Analyst's views, Cutaneous Squamous Cell Carcinoma Market Access and Reimbursement
Discover more about Cutaneous Squamous Cell Carcinoma Drugs in development @ Cutaneous Squamous Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Cutaneous Squamous Cell Carcinoma (cSCC)Market Overview at a Glance
4. Executive Summary of Cutaneous Squamous Cell Carcinoma (cSCC)
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Treatment and Management of Cutaneous Squamous Cell Carcinoma (cSCC)
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Cutaneous Squamous Cell Carcinoma (cSCC)Disease: 7 Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cutaneous Squamous cell Carcinom Treatment Market Size Report 2034: Emerging Therapies and Future Growth Opportunities here
News-ID: 4110755 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Cutaneous
Cutaneous Angiosarcoma Market New Product Development & Latest Trends
Introduction
Cutaneous angiosarcoma is a rare and aggressive malignancy that originates from endothelial cells lining blood vessels and lymphatics in the skin. Though it represents a small fraction of soft-tissue sarcomas, its high recurrence rates, metastatic potential, and poor prognosis make it one of the most challenging cancers to manage. The condition most frequently affects elderly patients and is often associated with chronic lymphedema, prior radiation exposure, or immunosuppression.
Traditional management has…
Emerging Trends Influencing The Growth Of The Cutaneous T-Cell Lymphoma Market: …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Cutaneous T-Cell Lymphoma Market Size Expected to Be by 2034?
The market for cutaneous T-cell lymphoma has witnessed substantial growth in the past few years. It is projected to rise from a size of $2.54 billion in 2024 to $2.72 billion in 2025, equating to a compound annual…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Key Trend Reshaping the Cutaneous Lupus Erythematosus Market in 2025: Advancemen …
What Are the Projections for the Size and Growth Rate of the Cutaneous Lupus Erythematosus Market?
The market size for cutaneous lupus erythematosus has seen quick expansion in the past few years. The growth is estimated to move from $2.24 billion in 2024 to $2.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. This considerable increase in the historic period is a result of factors such as…
Cutaneous Lupus Erythematosus Market Trends & Analysis Report 2024
"The Business Research Company recently released a comprehensive report on the Global Cutaneous Lupus Erythematosus Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
